

Charles M Lourenço

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3494961/publications.pdf>

Version: 2024-02-01

121
papers

7,593
citations

109137

35
h-index

58464

82
g-index

133
all docs

133
docs citations

133
times ranked

11890
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. <i>Nature Genetics</i> , 2012, 44, 1243-1248.	9.4	712
2	Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. <i>Nature Genetics</i> , 2009, 41, 829-832.	9.4	610
3	Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. <i>Nature Genetics</i> , 2014, 46, 503-509.	9.4	490
4	Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. <i>Lancet Neurology</i> , The, 2013, 12, 1159-1169.	4.9	473
5	Characterization of human disease phenotypes associated with mutations in <i>TREX1</i> , <i>RNASEH2A</i> , <i>RNASEH2B</i> , <i>RNASEH2C</i> , <i>SAMHD1</i> , <i>ADAR</i> , and <i>IFIH1</i> . <i>American Journal of Medical Genetics, Part A</i> , 2015, 167, 296-312.	0.7	447
6	Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. <i>New England Journal of Medicine</i> , 2016, 375, 545-555.	13.9	390
7	Clinical and Molecular Phenotype of Aicardi-Goutières Syndrome. <i>American Journal of Human Genetics</i> , 2007, 81, 713-725.	2.6	375
8	Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. <i>Journal of Medical Genetics</i> , 2017, 54, 288-296.	1.5	262
9	Mutations in CTC1, encoding conserved telomere maintenance component 1, cause Coats plus. <i>Nature Genetics</i> , 2012, 44, 338-342.	9.4	234
10	Joubert syndrome: a model for untangling recessive disorders with extreme genetic heterogeneity. <i>Journal of Medical Genetics</i> , 2015, 52, 514-522.	1.5	219
11	PNPLA6 mutations cause Boucher-Neuhäuser and Gordon Holmes syndromes as part of a broad neurodegenerative spectrum. <i>Brain</i> , 2014, 137, 69-77.	3.7	189
12	Alteration of Ganglioside Biosynthesis Responsible for Complex Hereditary Spastic Paraplegia. <i>American Journal of Human Genetics</i> , 2013, 93, 118-123.	2.6	151
13	Mutations in the Mitochondrial Methionyl-tRNA Synthetase Cause a Neurodegenerative Phenotype in Flies and a Recessive Ataxia (ARSAL) in Humans. <i>PLoS Biology</i> , 2012, 10, e1001288.	2.6	147
14	Recommendations for the detection and diagnosis of Niemann-Pick disease type C. <i>Neurology: Clinical Practice</i> , 2017, 7, 499-511.	0.8	119
15	Whole exome sequencing in patients with white matter abnormalities. <i>Annals of Neurology</i> , 2016, 79, 1031-1037.	2.8	116
16	Baraitser's Winter cerebrofrontofacial syndrome: delineation of the spectrum in 42 cases. <i>European Journal of Human Genetics</i> , 2015, 23, 292-301.	1.4	115
17	Mutations in SNORD118 cause the cerebral microangiopathy leukoencephalopathy with calcifications and cysts. <i>Nature Genetics</i> , 2016, 48, 1185-1192.	9.4	114
18	Mutations in CSPP1 Cause Primary Cilia Abnormalities and Joubert Syndrome with or without Jeune Asphyxiating Thoracic Dystrophy. <i>American Journal of Human Genetics</i> , 2014, 94, 62-72.	2.6	104

#	ARTICLE	IF	CITATIONS
19	<i><i>EPG5</i>-related Vici syndrome: a paradigm of neurodevelopmental disorders with defective autophagy. Brain, 2016, 139, 765-781.</i>	3.7	99
20	Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on “black bone disease” in Italy. European Journal of Human Genetics, 2016, 24, 66-72.	1.4	87
21	<i><i>DNM1</i> encephalopathy. Neurology, 2017, 89, 385-394.</i>	1.5	87
22	Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial. Brain, 2017, 140, 3112-3127.	3.7	87
23	Hereditary Spastic Paraplegia Type 43 (SPG43) is Caused by Mutation in <i><i>C19orf12</i>. Human Mutation, 2013, 34, 1357-1360.</i>	1.1	79
24	Plasma Lysosphingomyelin Demonstrates Great Potential as a Diagnostic Biomarker for Niemann-Pick Disease Type C in a Retrospective Study. PLoS ONE, 2014, 9, e114669.	1.1	75
25	Natural History of Vanishing White Matter. Annals of Neurology, 2018, 84, 274-288.	2.8	69
26	Expanding the genotypic spectrum of Perrault syndrome. Clinical Genetics, 2017, 91, 302-312.	1.0	68
27	Acrofacial Dysostosis, Cincinnati Type, a Mandibulofacial Dysostosis Syndrome with Limb Anomalies, Is Caused by POLR1A Dysfunction. American Journal of Human Genetics, 2015, 96, 765-774.	2.6	67
28	Clinical, pathological and functional characterization of riboflavin-responsive neuropathy. Brain, 2017, 140, 2820-2837.	3.7	64
29	Next Generation Molecular Diagnosis of Hereditary Spastic Paraplegias: An Italian Cross-Sectional Study. Frontiers in Neurology, 2018, 9, 981.	1.1	64
30	<i><i>KIAA0586</i> is Mutated in Joubert Syndrome. Human Mutation, 2015, 36, 831-835.</i>	1.1	62
31	Compound Heterozygosity of Low-Frequency Promoter Deletions and Rare Loss-of-Function Mutations in TXNL4A Causes Burn-McKeown Syndrome. American Journal of Human Genetics, 2014, 95, 698-707.	2.6	55
32	Non-coding deletions identify Maenli lncRNA as a limb-specific En1 regulator. Nature, 2021, 592, 93-98.	13.7	53
33	Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study. Lancet Diabetes and Endocrinology, 2020, 8, 594-605.	5.5	50
34	The SMAD-binding domain of SKI: a hotspot for de novo mutations causing Shprintzen “Goldberg syndrome. European Journal of Human Genetics, 2015, 23, 224-228.	1.4	48
35	Clinical, morphological, biochemical, imaging and outcome parameters in 21 individuals with mitochondrial maintenance defect related to <i><i>FBXL4</i> mutations. Journal of Inherited Metabolic Disease, 2015, 38, 905-914.</i>	1.7	45
36	Musculoskeletal Disease in MDA5-Related Type I Interferonopathy: A Mendelian Mimic of Jaccoud's Arthropathy. Arthritis and Rheumatology, 2017, 69, 2081-2091.	2.9	44

#	ARTICLE	IF	CITATIONS
37	Determinants of white matter hyperintensity burden in patients with Fabry disease. <i>Neurology</i> , 2016, 86, 1880-1886.	1.5	42
38	SLC35A2 ^{del} CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals. <i>Human Mutation</i> , 2019, 40, 908-925.	1.1	39
39	Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies. <i>PLoS Genetics</i> , 2017, 13, e1006683.	1.5	35
40	Chromosomal microarray analysis in the genetic evaluation of 279 patients with syndromic obesity. <i>Molecular Cytogenetics</i> , 2018, 11, 14.	0.4	35
41	Detection of copy number variations in epilepsy using exome data. <i>Clinical Genetics</i> , 2018, 93, 577-587.	1.0	35
42	SPG11 mutations cause widespread white matter and basal ganglia abnormalities, but restricted cortical damage. <i>NeuroImage: Clinical</i> , 2018, 19, 848-857.	1.4	33
43	Epilepsy in mucopolysaccharidosis disorders. <i>Molecular Genetics and Metabolism</i> , 2017, 122, 55-61.	0.5	29
44	Clinical and neuroimaging features of autosomal recessive spastic paraplegia 35 (SPG35): case reports, new mutations, and brief literature review. <i>Neurogenetics</i> , 2018, 19, 123-130.	0.7	29
45	Clinical, Biomarker, and Molecular Delineations and Genotype-Phenotype Correlations of Ataxia With Oculomotor Apraxia Type 1. <i>JAMA Neurology</i> , 2018, 75, 495.	4.5	28
46	Mucopolysaccharidosis II and III alpha/beta in Brazil: Analysis of the GNPTAB gene. <i>Gene</i> , 2013, 524, 59-64.	1.0	27
47	Biomolecules damage and redox status abnormalities in Fabry patients before and during enzyme replacement therapy. <i>Clinica Chimica Acta</i> , 2016, 461, 41-46.	0.5	27
48	De novo <i>DNM1</i> mutations in two cases of epileptic encephalopathy. <i>Epilepsia</i> , 2016, 57, e18-23.	2.6	27
49	Neurodevelopmental disorders associated with dosage imbalance of <i>ZBTB20</i> correlate with the morbidity spectrum of <i>ZBTB20</i> candidate target genes. <i>Journal of Medical Genetics</i> , 2014, 51, 605-613.	1.5	26
50	A Suspicion Index to aid screening of early-onset Niemann-Pick disease Type C (NP-C). <i>BMC Pediatrics</i> , 2016, 16, 107.	0.7	26
51	Endocrine and Growth Abnormalities in 4H Leukodystrophy Caused by Variants in <i>POLR3A</i> , <i>POLR3B</i> , and <i>POLR1C</i> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e660-e674.	1.8	26
52	Analyses of disease-related GNPTAB mutations define a novel GlcNAc-1-phosphotransferase interaction domain and an alternative site-1 protease cleavage site. <i>Human Molecular Genetics</i> , 2015, 24, 3497-3505.	1.4	25
53	Application of N-palmitoyl-O-phosphocholineserine for diagnosis and assessment of response to treatment in Niemann-Pick type C disease. <i>Molecular Genetics and Metabolism</i> , 2020, 129, 292-302.	0.5	24
54	Mutations, Clinical Findings and Survival Estimates in South American Patients with X-Linked Adrenoleukodystrophy. <i>PLoS ONE</i> , 2012, 7, e34195.	1.1	24

#	ARTICLE	IF	CITATIONS
55	Teratogenic effect of retinoic acid in swiss mice. <i>Acta Cirurgica Brasileira</i> , 2007, 22, 451-456.	0.3	23
56	New mutations in the ATM gene and clinical data of 25 AT patients. <i>Neurogenetics</i> , 2011, 12, 273-282.	0.7	23
57	Mutational screening of 320 Brazilian patients with autosomal dominant spinocerebellar ataxia. <i>Journal of the Neurological Sciences</i> , 2014, 347, 375-379.	0.3	23
58	New mutations in the GLA gene in Brazilian families with Fabry disease. <i>Journal of Human Genetics</i> , 2012, 57, 347-351.	1.1	22
59	SPG11-related parkinsonism: Clinical profile, molecular imaging and <sc>l</sc>-dopa response. <i>Movement Disorders</i> , 2018, 33, 1650-1656.	2.2	22
60	Analysis of the caregiver burden associated with Sanfilippo syndrome type B: panel recommendations based on qualitative and quantitative data. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 168.	1.2	22
61	Characterizing the phenotypic manifestations of MFN2 R104W mutation in Charcot-“Marie-“Tooth type 2. <i>Neuromuscular Disorders</i> , 2011, 21, 428-432.	0.3	21
62	Clinical, ophthalmological, imaging and genetic features in Brazilian patients with ARSACS. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 148-155.	1.1	21
63	New insights in mucopolysaccharidosis type VI: Neurological perspective. <i>Brain and Development</i> , 2014, 36, 585-592.	0.6	20
64	Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network. <i>Genetics and Molecular Biology</i> , 2014, 37, 23-29.	0.6	19
65	Biotinidase deficiency: Genotype-biochemical phenotype association in Brazilian patients. <i>PLoS ONE</i> , 2017, 12, e0177503.	1.1	19
66	Clinical and biochemical study of 29 Brazilian patients with metachromatic leukodystrophy. <i>Journal of Inherited Metabolic Disease</i> , 2010, 33, 257-262.	1.7	18
67	Mutations in the translocon-associated protein complex subunit <i>SSR3</i> cause a novel congenital disorder of glycosylation. <i>Journal of Inherited Metabolic Disease</i> , 2019, 42, 993-997.	1.7	18
68	Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 185.	1.2	17
69	Coexistence of two chronic neuropathies in a young child: Charcot-“marie-“tooth disease type 1A and chronic inflammatory demyelinating polyneuropathy. <i>Muscle and Nerve</i> , 2010, 42, 598-600.	1.0	16
70	Biotinidase deficiency: clinical and genetic studies of 38 Brazilian patients. <i>BMC Medical Genetics</i> , 2014, 15, 96.	2.1	16
71	Revealing the clinical phenotype of atypical neuronal ceroid lipofuscinosis type 2 disease: Insights from the largest cohort in the world. <i>Journal of Paediatrics and Child Health</i> , 2021, 57, 519-525.	0.4	15
72	X-linked adrenoleukodystrophy in heterozygous female patients: women are not just carriers. <i>Arquivos De Neuro-Psiquiatria</i> , 2012, 70, 487-491.	0.3	13

#	ARTICLE	IF	CITATIONS
73	Respiratory dysfunction in Charcot-Marie-Tooth disease type 1A. <i>Journal of Neurology</i> , 2015, 262, 1164-1171.	1.8	13
74	GNPTAB missense mutations cause loss of GlcNAc-1-phosphotransferase activity in mucopolipidosis type II through distinct mechanisms. <i>International Journal of Biochemistry and Cell Biology</i> , 2017, 92, 90-94.	1.2	11
75	Application of a glycinated bile acid biomarker for diagnosis and assessment of response to treatment in Niemann-pick disease type C1. <i>Molecular Genetics and Metabolism</i> , 2020, 131, 405-417.	0.5	11
76	Investigation of selected genomic deletions and duplications in a cohort of 338 patients presenting with syndromic obesity by multiplex ligation-dependent probe amplification using synthetic probes. <i>Molecular Cytogenetics</i> , 2014, 7, 75.	0.4	10
77	Psychiatric disorders, spinocerebellar ataxia type 3 and CAG expansion. <i>Journal of Neurology</i> , 2015, 262, 1777-1779.	1.8	10
78	Clinical findings in Brazilian patients with adult GM1 gangliosidosis. <i>JIMD Reports</i> , 2019, 49, 96-106.	0.7	10
79	Enzyme replacement therapy interruption in patients with Mucopolysaccharidoses: Recommendations for distinct scenarios in Latin America. <i>Molecular Genetics and Metabolism Reports</i> , 2020, 23, 100572.	0.4	10
80	Expanding the differential diagnosis of inherited neuropathies with non-uniform conduction: Andermann syndrome. <i>Journal of the Peripheral Nervous System</i> , 2012, 17, 123-127.	1.4	9
81	Quality of life in patients with Charcot-Marie-Tooth disease type 1A. <i>Arquivos De Neuro-Psiquiatria</i> , 2013, 71, 392-396.	0.3	9
82	TRAP1 ³ -CDG shows asymmetric glycosylation and an effect on processing of proteins required in higher organisms. <i>Journal of Medical Genetics</i> , 2021, 58, 213-216.	1.5	9
83	Clinical Characterization of Mucopolipidoses II and III: A Multicenter Study. <i>Journal of Pediatric Genetics</i> , 2019, 08, 198-204.	0.3	8
84	Novel clinical and genetic insight into CXorf56-associated intellectual disability. <i>European Journal of Human Genetics</i> , 2020, 28, 367-372.	1.4	8
85	Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence. <i>Gene</i> , 2013, 526, 150-154.	1.0	7
86	Recommendations for Evaluation and Management of Pain in Patients With Mucopolysaccharidosis in Latin America. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 146-152.	0.6	7
87	Maple syrup urine disease in Brazilian patients: variants and clinical phenotype heterogeneity. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 309.	1.2	7
88	Retinal Architecture in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS): Insights into Disease Pathogenesis and Biomarkers. <i>Movement Disorders</i> , 2021, 36, 2027-2035.	2.2	7
89	Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study. <i>Molecular Genetics and Metabolism</i> , 2021, 133, 94-99.	0.5	7
90	MECP2-related conditions in males: A systematic literature review and 8 additional cases. <i>European Journal of Paediatric Neurology</i> , 2021, 34, 7-13.	0.7	7

#	ARTICLE	IF	CITATIONS
91	Compound Charcot-Marie-Tooth disease may determine unusual and milder phenotypes. <i>Neurogenetics</i> , 2010, 11, 135-138.	0.7	6
92	Development of a Clinical Algorithm for the Early Diagnosis of Mucopolysaccharidosis III. <i>Journal of Inborn Errors of Metabolism and Screening</i> , 0, 8, .	0.3	6
93	GDAP1 mutations are frequent among Brazilian patients with autosomal recessive axonal Charcot-Marie-Tooth disease. <i>Neuromuscular Disorders</i> , 2021, 31, 505-511.	0.3	5
94	Evaluation of galsulfase for the treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 407-417.	0.5	4
95	Morquio-like dysostosis multiplex presenting with neuronopathic features is a distinct <sc><i>GLB1</i></sc>-related phenotype. <i>JIMD Reports</i> , 2021, 60, 23-31.	0.7	4
96	New novel mutations in Brazilian families with X-linked Charcot-Marie-Tooth disease. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 207-212.	1.4	3
97	Evaluation of 3-O-methyldopa as a biomarker for aromatic L-amino acid decarboxylase deficiency in 7 Brazilian cases. <i>Molecular Genetics and Metabolism Reports</i> , 2021, 27, 100744.	0.4	3
98	Challenges in familial chylomicronemia syndrome diagnosis and management across Latin American countries: An expert panel discussion. <i>Journal of Clinical Lipidology</i> , 2021, 15, 620-624.	0.6	3
99	Transthyretin <sc>Asp38Tyr</sc>: a new mutation associated to a late onset neuropathy. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 60-62.	1.4	2
100	Multicentric study on the diagnosis of Fabry's disease using angiokeratoma biopsy registries. <i>International Journal of Dermatology</i> , 2015, 54, e241-4.	0.5	2
101	Diagnosis and Management of Classical Homocystinuria in Brazil. <i>FIRE Forum for International Research in Education</i> , 2018, 6, 232640981878890.	0.7	2
102	Sanfilippo Syndrome: The Tale of a Challenging Diagnosis. <i>Journal of Inborn Errors of Metabolism and Screening</i> , 0, 8, .	0.3	2
103	Metachromatic leukodystrophy: pediatric presentation and the challenges of early diagnosis. <i>Revista Da Associação Médica Brasileira</i> , 2020, 66, 1344-1350.	0.3	2
104	High glucose level as a modifier factor in CMT1A patients. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 132-137.	1.4	1
105	Sapropterin dihydrochloride therapy in dihydropteridine reductase deficiency: Insight from the first case with molecular diagnosis in Brazil. <i>JIMD Reports</i> , 2021, 61, 19-24.	0.7	1
106	Mutação missense de novo patogênica c.2415C G (p.Asp805Glu) no gene ATP1A3 em paciente com hemiplegia alternante da infância com resposta favorável ao cloridrato de biperideno. <i>Medicina</i> , 2021, 54, .	0.0	1
107	Acute hepatic porphyria: when to perform liver transplantation?. <i>Medicina</i> , 2021, 54, .	0.0	1
108	Disease duration and survival in Brazilian Niemann-Pick disease type C patients: Preliminary data on potential impact of miglustat. <i>Molecular Genetics and Metabolism</i> , 2016, 117, S50-S51.	0.5	0

#	ARTICLE	IF	CITATIONS
109	Pitfalls and potential clues in diagnosis in attenuated form of Hunter syndrome. <i>Molecular Genetics and Metabolism</i> , 2019, 126, S62-S63.	0.5	0
110	Against all odds: enzyme replacement therapy in non-ambulatory and ambulatory Morquio syndrome type A patients. <i>Molecular Genetics and Metabolism</i> , 2019, 126, S32.	0.5	0
111	Clinical and biochemical study of Brazilian patients with metachromatic leukodystrophy. <i>Molecular Genetics and Metabolism</i> , 2019, 126, S42-S43.	0.5	0
112	Hurler syndrome: Severe sleep apnea as initial presentation in a 10-month-old child. <i>Molecular Genetics and Metabolism</i> , 2019, 126, S61.	0.5	0
113	ATAXIA DE FRIEDREICH: RELATO DE CASO DE IRMÃOS COM FENÓTIPOS CLÍNICOS DISCORDANTES. , 0, , 362-372.		0
114	Chudley-McCullough Syndrome: Case Report and the Role of Neuroimaging to Suggest the Diagnosis. <i>Journal of Pediatric Neurology</i> , 0, , .	0.0	0
115	Hipoventilação relacionada ao sono de origem central secundária à deficiência de biotinidase: relato de caso. <i>Medicina</i> , 2021, 54, e166390.	0.0	0
116	SÍNDROME DE CANTÃO: O PRIMEIRO BRASILEIRO COM MUTAÇÃO CONFIRMADA DO GENE ABCC9. , 2019, , .		0
117	A INFLUÊNCIA DO HIV EM INFECÇÕES OPORTUNISTAS DO SISTEMA NERVOSO CENTRAL. , 2019, , .		0
118	Perthes-Like Disease Masquerading Non-Classical MPS. <i>Journal of Inborn Errors of Metabolism and Screening</i> , 0, 8, .	0.3	0
119	Uso de canabidiol como terapia adjuvante em paciente com síndrome de Zellweger: relato de caso. <i>Medicina</i> , 2020, 53, 321-326.	0.0	0
120	Paraparesia espástica complicada como fenótipo neurológico em OPA1. <i>Medicina</i> , 2021, 54, .	0.0	0
121	Desafios do diagnóstico da hipofosfatase em adultos. <i>Medicina</i> , 2022, 55, .	0.0	0